Erythropoietin (EPO) produced by the fetal liver and adult kidney is an essential stimulator of erythropoiesis. EPOproduction is regulated through hypoxic activation of gene transcription and possibly hypoxia-induced stabilization of its mRNA.In the liver of early embryos in which EPO production poorly responds to hypoxia, retinoic acid may be an important stimulator. In this decade, new sites of EPOproduction have been found: central nervous system and reproductive organs. These tissues have a paracrine and/or autocrine system of EPO, which is independent of the endocrine system (kidney/ bone marrow) in adult erythropoiesis. In the central nervous system, astrocytes are the main producers of EPO, while EPO receptor is expressed in neurons. EPO protects neurons from a various types of damage. The uterine EPO is likely involved in the estrogen-dependent angiogenesis of the endometrial layer. The possible functions of EPOin other tissues and tissue-characteristic regulation of EPO production are also discussed in this review.
Introduction
As Fig. 1 shows, human erythropoietin (hEPO) consists of 165 amino acids, and three N-linked (Asn-X-Thr/Ser) glycans and one O-linked glycan (1) . The relative molecular mass of the protein backbone deduced from the primary sequence is 18,398 (2, 3) but recombinant hEPO (rhEPO) and urinary EPO migrate in SDS gel with a molecular size of 34,000-37,000 (4) due to glycosylation. N-glycans that are fully sialylated are important for long-life in the circulation (see citations in ref.l); removal of sialic acids results in the complete loss of the in vivo activity. N-glycosylation is required for proper biosynthesis and/or efficient secretion. Nglycans also affect the affinity of EPOto the receptor but do not play a key role in the expression of the in vitro activity; EPOwith less sialylated N-glycans shows a higher affinity to EPO receptor (5) . O-linked glycan appears to be of little importance because it is lacking in rodent EPO. In hEPO, two disulfide bonds, Cys7-Cysl61 and Cys29-Cys33, are formed (6). The disulfide bond Cys7-Cysl61 is crucial for the preservation of the molecular structure. Figure 1 also includes the amino acid sequences deduced from cDNAs of monkeys (7), rats (8) and mice (9). EPO from all of these animals crossbinds with EPOreceptors of others and can transmit its signal for survival, proliferation and differentiation of target erythroid precursor cells. EPO signaling occurs through ligand-induced receptor homodimerization, followed by stable association of Janus kinase-2 (Jak2), an intracellular tyrosine kinase, to the intracellular domain of the receptor, phosphorylation of Jak2, EPOreceptor, and Stat5 (signal transducer and activator of transcription) (10).
EPOproduced by the fetal liver and adult kidney is the primary stimulator of red blood cell formation. A major signal regulating EPO production in the kidney is the oxygen concentration, while that in the liver of early embryos appears to be regulated in a different manner as described below. EPOproduction is markedly enhanced under hypoxia through transcriptional activation of the EPO gene; EPO mRNA expression is induced under hypoxia through accumulation of a transcriptional factor HIF-1 (hypoxia-inducible factor-1) (ll-14).
Most, if not all, of hypoxia-inducible genes contain HIF-1 binding sites, highly conserved sequences (5 'RCGTG3 '), called the hypoxia-response element. HIF-1 consists of heterosubunits, a and p. Subunit p was a known protein called ARNT(aryl hydrocarbon nuclear receptor translocator), while subunit a was a new protein. Levels of both mRNAs are relatively constant irrespective of oxygen concentration. HIF-1p exists abundantly regardless of cellular oxygenation, while HIF-1a is virtually undetectable under normoxia. Under normoxia, HIF-1a is rapidly degraded via ubiquitin-proteasome system. Intracellular proline Figure 1 . Amino acid sequences of human, monkey, mouse, and rat EPO(1). Numbering starts from N-terminus of mature EPO.N-glycosylation sites are shown by asterisks, and an O-glycosylation site is indicated by arrows. The disulfide bonds are drawn as bridges. The C-terminal arginine residue (R) is missing in human urinary EPO and recombinant human EPO by unknown reason.
hydroxylase that requires oxygen and iron for its activity hydroxylates specific proline residues in HIF-la under normoxia, which triggers rapid degradation of HIF-la.
Under hypoxia, HIF-la is stabilized probably by inactivation of proline hydroxylase due to the deficiency of oxygen, and an elevated level of the complex, ap, activates EPOgene transcription. The proline hydroxylase maybe an oxygen sensor long sought in animals. In addition, hypoxia-induced stabilization of EPOmRNA also significantly contributes to EPO production and p38a MAPkinase is involved in this stabilization pathway (15). Whatever the mechanism is, a hypoxia-induced increase of EPOin the blood stimulates the formation of red blood cells, resulting in improvement of the oxygen supply and eventually repression of the activated gene transcription and/or EPO mRNA stabilization. Erythropoietic stimulation has been believed to be the sole physiological function of EPO. In the last decade, however, findings that EPO may have more physiological functions have accumulated; the central nervous system and reproductive organs have been found to produce EPO. In this review, I discuss the possible roles of EPOin these new sites and the characteristics of regulation of EPOproduction at these sites, which markedly differ from those of the kidney. Experimental results suggesting functions of EPOin other tissues are also summarized.
Here I must add that there is a recent report that mice engineered to restrict EPOreceptor expression in the erythroid system are apparently normal, throwing doubt on multiple functions of EPO(16). It should be noted, however, that disruption of a gene often yields phenotypes that are unexpected from experimental results found with the wild type. The gene-engineered animals may evolve backup. Further investigation including examination of mice given a load such as oxygen deficiency may reveal difference between engineered and wild-type animals.
Erythropoietin and Its Receptor in the Brain
A survey of rat organs has revealed hypoxia-inducible expression of EPO mRNAin the testis, brain, liver and kidney (17 more recently it has been shownthat neurons also produce EPO (20) , the main producer of EPO in the brain is astrocytes.
Expression of the functional EPO receptor has been found in neuronal cell lines such as PC12; binding of EPOcauses a rapid and transient Ca2+influx via plasma membraneCa2+ channels (21-23). EPO also increases the intracellular monoamines, dopamine release, and tyrosine hydroxylase activity (21, 22), and supports cell survival when cultured without serum and NGF(22). EPOaugments choline acetyltransferase in mouse embryonic primary septal neurons (24). EPO receptor is expressed in primary cultured neurons prepared from the hippocampus and cerebral cortex of rat fetuses (25).Specific binding sites of radioiodinated EPO are present in some defined areas of the adult mouse brain including the hippocampus and cerebral cortex, where the neurons are highly vulnerable to ischemia (26). Messenger RNAof EPO receptor is abundantly expressed in the brain of mouse early embryos and its level is dramatically reduced during development (27), suggesting that EPOmight play an unidentified role in brain development. The central nervous system of primates including humans also expresses EPOand its receptor (19, 28, 29) . It is unlikely that the renal EPO crosses the blood-brain barrier under physiological conditions. Thus, the central nervous system has a paracrine EPO/EPOreceptor system that is independent of the endocrine system (kidney/ bone marrow and spleen) for erythropoiesis. EPOproduced by astrocytes contains fewer sialic acids and therefore has a higher affinity to the receptor (18). It appears that kidney EPOis abundantly sialylated, thereby preventing rapid disappearance from the circulation, while astrocyte EPOis less sialylated, thereby taking precedence of high affinity to the receptor because EPOin the brain acts in a paracrine manner. These findings facilitated intensive experiments to elucidate the possible role of EPOin the brain.
Neuroprotective Action of Erythropoietin
In vivo neuroprotective action Based on the hypoxic induction of brain EPO, we hypothesized that brain EPO contributes to neuron survival under ischemia, and the following experimental results strongly support our hypothesis. In a gerbil forebrain ischemia model, intracerebro-ventricular infusion of EPO ameliorates the ischemia-induced loss of synapses in the hippocampal CA1 field which contains neurons highly vulnerable to ischemic insult, and eventually alleviates neuron death and learning disability ( Fig Expression of EPOand its receptor has been found in retina (35) . Neutralization of endogenous EPO with soluble EPOR,which is the same procedure taken to demonstrate the in vivo function of EPO in the brain (31), exacerbates ischemic injury of retinal neurons, indicating that EPOproduced in retina protects retinal neurons from ischemic death (36) . Systemic administration of EPOprotects retinal neurons from acute ischemia-reperfusion injury (36) and lightinduced degeneration (35) , indicating that EPOcrosses the blood-retina barrier. A large dose of EPO (5,000 units/kg) was given intraperitoneally in both experiments.
In addition to the direct protective effect of EPOon neurons, EPOmayexert its neuroprotective action through an improved blood supply by vascular relaxation (37, 38) or neovascularization (39 Binding of EPO induces receptor homodimerization, which results in activation of Jak2, an intracellular tyrosine kinase (10). The activated Jak2 phosphorylates Stat5, leading erythroid precursor cells to cell proliferation and differentiation. EPOalso supports the survival of erythroid precursor cells by inducing the expression of Bcl-X, a member of the Bcl-2 family that acts as an anti-apoptotic protein (48) . Digicaylioglu and Lipton investigated the EPO-induced neuroprotective pathway by the use of cultured cerebrocortical neurons (49) . They showed that EPO prevented NOinduced cell death by triggering cross-talk between Jak2 and angiogenesis in the estrus cycle. Arecent paper of humans has indicated that the humanuterus expresses EPOmRNA in a menstrual cycle-dependent manner (50), which supports our findings of mice. Mouseoviduct and ovary also produce EPOin an estrogen-dependent mannerbut wedo not know its physiological significance (5 1). An increased serum level of EPOin pregnant womenmay be derived from Epo produced by these organs because the estrogen level is maintained to be high during pregnancy (52) . Manymalignant tumors from the ovary and uterus express EPOand its receptor (53) . Inhibition of EPOsignaling destroyed ovarian and uterine tumors in grafted nude mice, suggesting that EPOmay be involved in the initiation and/or development of these tumors. EPO level is elevated in the peritoneal fluid of womenwith endometriosis and the elevation is significant in the initial stage of the disease (54). Wefound that the cultured mouse epididymis produces EPO (58) . The content of EPO mRNAin the epididymis from the adult mouse amounts to 40%of that in the kidney, suggesting that male reproductive organ-derived EPOcontributes to its level in blood. The epididymal EPO mRNA was dramatically increased upon growth, and hypoxia induced epididymal EPO mRNA.The epididymis consists of the interstitial tissue and the ductus epididymidis, an extremely tortuous duct, in which spermatozoa exported from the testis gain motility and fertilizing capacity. The site of EPOproduction was located in the interstitial space between ductus epididymidis. The epididymal EPOmay have an unidentified function in the male reproductive organ. It is of interest that administration of EPOto rats stimulated sperm maturation and improved fertilizing capacity (59) , because the epididymis is the site where spermatozoa mature.
Erythropoietin Receptor in Other Tissues
Myoblasts express EPO receptor and binding of EPO stimulates cell proliferation and represses cell differentiation (60) . EPOreceptor has been shown to be expressed in the kidney cells and binding of EPO stimulates cell growth (61) . Human milk contains substantial concentrations of EPO, suggesting a pleiomorphic role in erythropoiesis, neurodevelopment and maturation of the gut in neonates (62, 63) .
Regulation of Erythropoietin Production
Brain and kidney Exposure of mice to hypoxia (7% oxygen) markedly elevates serum EPO, and EPOmRNA in the kidney and cerebrum (64) . However, the levels of serum EPOand renal EPO mRNAare quickly lowered despite continuous hypoxia.
Surprisingly,
brain EPO mRNAis sustained at a high level for at least 24 h (Fig. 3A) . Since hematocrit values are unchanged during experiments, the rapid decline of renal EPO mRNAis not due to the operation of the classical negativefeedback inhibition (EPO gene expression is repressed through the improved oxygen delivery by the increased erythrocytes).
Although the mechanism for the rapid decrease in the kidney remains unknown,this notable difference in the temporal patterns of hypoxia inducibility of EPO mRNA between the kidney and brain seems to well reflect the tissue-specific functions of EPO. In the brain, EPOsupports neuron survival under ischemia, and therefore a high Femalereproductive organs Therole of EPOin the uterine angiogenesis raises a possibility that the uterus produces EPO in an estrogendependent manner,becauseit is hard to speculate that the renal EPO is responsible for the periodical angiogenesis in the uterus. In fact, in vitro cultured uterus fromovariectomizedmouseexpressedEPOprotein andits mRNA in an estrogen-dependentmanner (40) . Administration of estrogen to the ovariectomizedmouseinduced a rapid and transient increase in EPOmRNA in the uterus (Fig. 3B) . Interestingly, the uterine EPOmRNA is hypoxia-inducible only in the presence of estrogen. Although the magnitude(2.5-fold) of 
